The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Caco‐2 cells as a model for intestinal lipoprotein synthesis and secretion
Abstract
Caco‐2 cells, an intestinal cell line derived from a human colorectal carcinoma that spontaneously differentiates under standard culture conditions, lends itself to the in vitro study of human gut in view of its efficient intestinal transport processes. Among its multiple biological functions are those related to the absorption, transport, and metabolism of lipids and lipoproteins. Despite their intestinal origin, confluent Caco‐2 cell monolayers primarily express L‐FABP for the uptake of apical dietary long chain fatty acids, incorporating them into triglycerides by the glycerol 3‐phosphate pathway, and assembling very‐low‐density lipoprotein, high‐density lipoprotein, and low‐density lipoprotein. The monoacylglycerol pathway is inactive in Caco‐2 cells. Furthermore, the secretion of newly synthesized triglyceride‐rich lipoproteins is very restricted, despite abundant production of apolipoprotein (apo) B. The regulation of apoB synthesis and its mRNA editing at the enterocyte level has been intensively examined in Caco‐2 cells. Luminal fatty acids, calcium ion, as well as vitamins and hormones are known to modulate the apoB‐48/apoB‐100 at the transcriptional and/or translational level. The regulation of 3‐hydroxy‐3‐methylglutaryl‐CoA reductase and acyl‐CoA: (cholesterol acyltransferase), the key enzymes governing intracellular cholesterol handling, have also been extensively examined in Caco‐2 cells. In many respects this cell line provides an excellent in vitro model for the investigation of intestinal lipoprotein metabolism; however, their limited secretion capacity remains a potential drawback to comparisons with the in vivo physiological state.—Levy, E., Mehran, M., Seidman, E. Caco‐2 cells as a model for intestinal lipoprotein synthesis and secretion. FASEB J. 9, 626‐635 (1995)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hidalgo, I. J., Raub, T. J., & Borchardt, R. T. (1989) · Gastroenterology · doi:10.1016/s0016-5085(89)80072-1 · Cited by 2,396
Cited by
Lipids and Lipid-Based Formulations: Optimizing the Oral Delivery of Lipophilic Drugs
Porter, C. J. H., Trevaskis, N. L., & Charman, W. N. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2197 · Cited by 1,824
“In the drug development field, Caco-2 cells are well known as a high-throughput screen for the assessment of intestinal drug permeability, but this cell line is also used in lipid biochemistry to examine aspects of intracellular lipoprotein assembl”
BackgroundChylomicrons promote intestinal absorption of lipopolysaccharides
Ghoshal, S., Witta, J., Zhong, J., de Villiers, W., & Eckhardt, E. (2009) · Journal of Lipid Research · doi:10.1194/jlr.m800156-jlr200 · Cited by 662
“CaCo-2 cells, cultured on permeable supports (“transwells”) as a model for small-intestinal enterocytes (36).”
BackgroundLipid-Based Delivery Systems and Intestinal Lymphatic Drug Transport: A Mechanistic Update
Trevaskis, N. L., Charman, W. N., & Porter, C. J. H. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.09.007 · Cited by 442
Lipid – An emerging platform for oral delivery of drugs with poor bioavailability
Chakraborty, S., Shukla, D., Mishra, B., & Singh, S. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2009.06.001 · Cited by 411
Lipid-based formulations for intestinal lymphatic delivery
O’Driscoll, C. M. (2002) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(02)00051-9 · Cited by 372
Metadata
- Authors
- Levy, E., Mehran, M., & Seidman, E.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 1995-05
- Volume
- 9
- Issue
- 8
- Pages
- 626-635
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W1528470195
- Cited by
- 205
- References
- 1
- FWCI
- 7.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.